Drug intelligence / Profile preview

PLD-104

Development stage: Preclinical
Lead developer: Pelemed
Modality: Small Molecules

Overview

PLD-104 is a small molecule RET inhibitor being developed by Pelemed for the treatment of Non-Small Cell Lung Cancer (NSCLC). It is specifically engineered to target drug-resistant RET mutations, such as those that arise following treatment with first-generation RET inhibitors. The drug is currently in the discovery phase and utilizes Pelemed's medicinal chemistry platform to address unmet needs in patients with RET-fusion positive or RET-mutant cancers that have developed resistance mechanisms.

Targets

RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on PLD-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLD-104.

Explore the full profile